Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Development of novel anti-cancer immunotherapy against mesothelioma comprising of oncolytic adenovirus vectors armed with ICOS and CD40 ligands in combination with checkpoint inhibitors anti-PD-1 and anti-CTLA-4

2022/47/D/NZ7/03212

Keywords:

immuno-oncology oncolytic adenoviruses CD40 ligand ICOS ligand checkpoint inhibitors anti-PD-1 anti-CTLA-4 preclinical studies

Descriptors:

  • NZ6_005:
  • NZ7_014:

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Narodowy Instytut Zdrowia Publicznego - Państwowy Zakład Higieny (NIZP - PZH)

woj. mazowieckie

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr Łukasz Kuryk 

Number of co-investigators in the project: 5

Call: SONATA 18 - announced on 2022-07-15

Amount awarded: 1 930 370 PLN

Project start date (Y-m-d): 2023-07-06

Project end date (Y-m-d): 2026-07-05

Project duration:: 36 months (the same as in the proposal)

Project status: Pending project

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Publication in academic press/journals (4)
  1. Novel combinatorial therapy of oncolytic adenovirus AdV5/3- D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model
    Authors:
    Mariangela Garofalo, Magdalena Wieczorek, Ines Anders, Monika Staniszewska, Michal Lazniewski4, Marta Prygiel, Aleksandra Anna Zasada, Teresa Szczepinska, Dariusz Plewczynski, Stefano Salmaso, Paolo Caliceti, Vincenzo Cerullo, Ramon Alemany, Beate Rinner, Katarzyna Pancer and Lukasz Kuryk
    Academic press:
    Frontiers in Oncology (rok: 2023, tom: 13, strony: 46035), Wydawca: Frontiers
    Status:
    Published
    DOI:
    10.3389/fonc.2023.1259314 - link to the publication
  2. Extracellular vesicles powered cancer immunotherapy: Targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model
    Authors:
    Sara Mathlouthi, Lukasz Kuryk, Marta Prygiel, Maria Giovanna Lupo, Aleksandra Anna Zasada, Cristiano Pesce, Nicola Ferri, Beate Rinner, Stefano Salmaso, Mariangela Garofalo
    Academic press:
    Journal of Controlled Release (rok: 2024, tom: 376, strony: 777–793), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.057 - link to the publication
  3. Cancer vaccines: an update on recent achievements and prospects for cancer therapy
    Authors:
    Arezki Chekaoui, Mariangela Garofalo, Beata Gad, Monika Staniszewska, Jacopo Chiaro, Katarzyna Pancer, Aleksander Gryciuk, Vincenzo Cerullo, Stefano Salmaso, Paolo Caliceti, Aleksander Masny, Magdalena Wieczorek, Sari Pesonen & Lukasz Kuryk
    Academic press:
    Clinical and Experimental Medicine (rok: 2024, tom: 25, strony: 46044), Wydawca: Springer Nature
    Status:
    Published
    DOI:
    10.1007/s10238-024-01541-7 - link to the publication
  4. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model
    Authors:
    Lukasz Kuryk, Sara Mathlouthi, Magdalena Wieczorek, Beata Gad, Beate Rinner, Alessio Malfanti, Francesca Mastrotto, Stefano Salmaso, Paolo Caliceti, Mariangela Garofalo
    Academic press:
    European Journal of Pharmaceutics and Biopharmaceutics (rok: 2024, tom: 199, strony: 114300), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.ejpb.2024.114300 - link to the publication

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy